step 1 semaglutide 2.4 mg weight loss percent Now that oral (#wegovy) is available, people want to know more about how the oral and injectable forms compare. First slide is the trial design. Second slide is average #weightloss of Once-weekly 2.4 mg Semaglutide for

Cardiovascular Benefits : Studies show that Semaglutide can reduce the risk of major cardiovascular events, such as heart attacks and strokes, in certain patients

Modified-release formulations are available and may be better tolerated by some patients

SELECT: Semaglutides Rapid Cardiovascular Benefits (data from #ECO2025) In adults with obesity & established CVD (no diabetes), semaglutide 2.4 mg weekly: MACE by 41% within 6 months First significant benefit seen at day 20 53% in , 43% in nonfatal MI Early protectionbeyond weight loss

If IGF-1, glucose, or other markers move outside of expected ranges, scale back or stop dosing

Eating speed also impacts nausea severity